Founded in Paris in 1920, Gide is a leading international law firm with 12 offices spread throughout the world.
Gide is physically present in six regions of the world, with 11 offices, enabling it to act on cases globally.
24 February 2017
Deals | France | Capital Markets
Inventiva, a biopharmaceutical company developing innovative therapies, particularly to treat fibrosis, announced on 14 February its successful initial public offering on Compartment C of Euronext regulated market in Paris. The settlement date of the EUR-48-million operation was 16 February 2017. The funds raised will enable Inventiva to pursue the clinical development of IVA337 programme for the treatment of NASH and systemic sclerosis until the end of the clinical studies of phase IIb, and to pursue the clinical development of IVA 336 in MPS notably for the treatment of the Maroteaux-Lamy syndrome (MPS VI). The balance will be used to pursue the development of the Company’s preclinical portfolio, particularly the Yap-Tead programme.
Inventiva was advised by Gide with partner Arnaud Duhamel, assisted by counsel Théophile Strebelle, Aude-Laurène Dourdain, Louis Ravaud and Emilie Leygonie, on securities and corporate law aspects, and partner Melinda Arsouze, assisted by Scott Logan and Amine Assouad, on US law aspects.
Société Générale and KBC Securities were advised by Brandford Griffith & Associés on securities law aspects, and Clifford Chance on US law aspects.
